Market Overview

Analyst: Amazon's Entry Into Pharmacy Is All But Certain At This Point

Share:
Analyst: Amazon's Entry Into Pharmacy Is All But Certain At This Point
Related AMZN
UPS Pilots Keyless Deliveries In New York City
Today's Pickup: More Assertive EU Signs Massive Trade Deal With Japan
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q2 2018 Update (Seeking Alpha)
Related HUM
7 Biggest Price Target Changes For Monday
10 Biggest Price Target Changes For Friday

Pharmacy and health care investors should brace themselves — Amazon.com, Inc (NASDAQ: AMZN) is coming. In a pair of new research notes out this week, analysts at Leerink said it’s not a matter of if Amazon will make a move into the prescription drug business, it’s a matter of when and how.

On Thursday, analyst David Larsen said he expects Amazon to officially announce its move into the pharmacy business within two years' time (see Larsen's track record here). With roughly 75 million Prime subscribers and nearly unlimited resources, Larsen said Amazon will likely make a huge impact.

“We are incrementally more cautious on the PBM and retail space given the threat of a new entrant,” Larsen wrote.

On Friday, analyst Ana Gupte said Amazon’s technology and infrastructure are also huge advantages when it comes to gaining pharmacy market share (see Gupte's track record here).

“AMZN is a meaningful competitive threat to existing players in the drug value chain with its best-in-class mail order fulfillment platform and easy-to-use one stop shopping Retail Pharmacy experience,” Gupte said.

For investors, Gupte said pharmacy retailers that are most threatened by Amazon include Walgreens Boots Alliance Inc (NASDAQ: WBA), CVS Health Corp (NYSE: CVS) and Wal-Mart Stores Inc (NYSE: WMT).

The potential impact on Express Scripts Holding Company (NASDAQ: ESRX) is much less clear. Gupte said Amazon could be a positive or a negative for Express depending on the approach it decides to take. If Amazon decides to take the Whole Foods route to enter the PBM market, Express is the most likely target for a buyout. If not, it could be the most exposed to Amazon’s self-built business.

Gupte noted that UnitedHealth Group Inc (NYSE: UNH) and Humana Inc (NYSE: HUM) are potentially insulated from Amazon.

Related Link: Drug Stores Next On The Amazon Hit List?

Latest Ratings for AMZN

DateFirmActionFromTo
Jul 2018Credit SuisseMaintainsOutperformOutperform
Jul 2018BarclaysMaintainsOverweightOverweight
Jul 2018Cowen & Co.MaintainsOutperformOutperform

View More Analyst Ratings for AMZN
View the Latest Analyst Ratings

Posted-In: Ana GupteAnalyst Color Biotech Health Care Top Stories Analyst Ratings Tech General Best of Benzinga

 

Related Articles (AMZN + CVS)

View Comments and Join the Discussion!